Baxter International (BAX) Stock Price
Baxter International Price
Over the last 19 years Baxter International grew revenue by 0.4% annually, reaching 11.24 B USD. Earnings per share have grown at 5.5% per year over the last 17 years. For Baxter International, the net margin of -8.5% is down versus 10.6% a few years ago. At today's price the dividend yield works out to roughly 1.93%. The consensus 12-month price target for Baxter International is 22.44 USD, about 16.9% below where the stock trades today. Of 25 analysts, 2 rate the stock a buy — an overall Hold consensus. The stock trades about 71% above its 52-week low.
Baxter International stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Baxter International over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Baxter International stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Baxter International's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Baxter International Price |
|---|---|
| 8/6/2026 | 27.01 USD |
| 8/5/2026 | 27.61 USD |
| 8/4/2026 | 27.70 USD |
| 8/3/2026 | 28.10 USD |
| 7/31/2026 | 26.16 USD |
| 7/30/2026 | 26.75 USD |
| 7/29/2026 | 24.73 USD |
| 7/27/2026 | 23.28 USD |
| 7/23/2026 | 21.67 USD |
| 7/22/2026 | 21.74 USD |
| 7/21/2026 | 22.21 USD |
| 7/20/2026 | 22.07 USD |
| 7/17/2026 | 22.61 USD |
| 7/16/2026 | 23.35 USD |
| 7/15/2026 | 22.15 USD |
| 7/14/2026 | 21.80 USD |
| 7/13/2026 | 22.73 USD |
| 7/10/2026 | 22.62 USD |
| 7/9/2026 | 22.46 USD |
| 7/8/2026 | 22.33 USD |
| 7/7/2026 | 22.86 USD |
| 7/6/2026 | 22.28 USD |
| 7/2/2026 | 22.65 USD |
| 7/1/2026 | 21.69 USD |
| 6/30/2026 | 21.32 USD |
| 6/29/2026 | 22.00 USD |
| 6/26/2026 | 22.04 USD |
| 6/25/2026 | 21.55 USD |
| 6/24/2026 | 21.04 USD |
| 6/23/2026 | 20.10 USD |
| 6/22/2026 | 19.82 USD |
| 6/18/2026 | 19.96 USD |
| 6/17/2026 | 20.24 USD |
| 6/16/2026 | 20.58 USD |
| 6/15/2026 | 20.97 USD |
| 6/12/2026 | 20.71 USD |
| 6/11/2026 | 20.16 USD |
| 6/10/2026 | 20.57 USD |
| 6/9/2026 | 20.03 USD |
| 6/8/2026 | 19.24 USD |
| 6/5/2026 | 19.68 USD |
| 6/4/2026 | 19.22 USD |
| 6/3/2026 | 18.45 USD |
| 6/2/2026 | 18.95 USD |
| 6/1/2026 | 18.31 USD |
| 5/29/2026 | 19.10 USD |
| 5/28/2026 | 19.17 USD |
| 5/27/2026 | 19.65 USD |
| 5/26/2026 | 19.40 USD |
| 5/22/2026 | 19.15 USD |
| 5/21/2026 | 18.69 USD |
| 5/20/2026 | 18.32 USD |
| 5/19/2026 | 18.33 USD |
| 5/18/2026 | 17.79 USD |
| 5/15/2026 | 17.30 USD |
| 5/14/2026 | 17.78 USD |
| 5/13/2026 | 17.31 USD |
| 5/12/2026 | 17.89 USD |
| 5/11/2026 | 17.53 USD |
| 5/8/2026 | 17.99 USD |
| 5/7/2026 | 17.49 USD |
| 5/6/2026 | 16.98 USD |
| 5/5/2026 | 16.75 USD |
| 5/4/2026 | 16.62 USD |
| 5/1/2026 | 17.21 USD |
| 4/30/2026 | 17.58 USD |
| 4/29/2026 | 16.90 USD |
| 4/28/2026 | 17.94 USD |
| 4/27/2026 | 18.49 USD |
| 4/24/2026 | 18.16 USD |
| 4/23/2026 | 18.41 USD |
| 4/22/2026 | 18.31 USD |
| 4/21/2026 | 18.49 USD |
| 4/20/2026 | 18.84 USD |
| 4/17/2026 | 18.71 USD |
| 4/16/2026 | 18.14 USD |
| 4/15/2026 | 17.60 USD |
| 4/14/2026 | 17.59 USD |
| 4/13/2026 | 17.63 USD |
| 4/10/2026 | 17.15 USD |
| 4/9/2026 | 17.30 USD |
| 4/8/2026 | 17.24 USD |
| 4/7/2026 | 16.62 USD |
| 4/6/2026 | 16.65 USD |
| 4/2/2026 | 16.68 USD |
| 4/1/2026 | 16.78 USD |
| 3/31/2026 | 16.80 USD |
| 3/30/2026 | 15.80 USD |
| 3/27/2026 | 15.97 USD |
| 3/26/2026 | 16.67 USD |
| 3/25/2026 | 17.12 USD |
| 3/24/2026 | 16.72 USD |
| 3/23/2026 | 16.61 USD |
| 3/20/2026 | 16.15 USD |
| 3/19/2026 | 16.66 USD |
| 3/18/2026 | 17.09 USD |
| 3/17/2026 | 17.62 USD |
| 3/16/2026 | 17.08 USD |
| 3/13/2026 | 17.40 USD |
| 3/12/2026 | 18.01 USD |
| 3/11/2026 | 18.05 USD |
| 3/10/2026 | 17.46 USD |
| 3/9/2026 | 17.91 USD |
| 3/6/2026 | 17.69 USD |
| 3/5/2026 | 18.60 USD |
| 3/4/2026 | 19.03 USD |
| 3/3/2026 | 19.03 USD |
| 3/2/2026 | 19.69 USD |
| 2/27/2026 | 20.37 USD |
| 2/26/2026 | 20.36 USD |
| 2/25/2026 | 20.73 USD |
| 2/24/2026 | 20.63 USD |
| 2/23/2026 | 21.26 USD |
| 2/20/2026 | 21.58 USD |
| 2/19/2026 | 21.34 USD |
| 2/18/2026 | 21.87 USD |
| 2/17/2026 | 20.74 USD |
| 2/13/2026 | 19.79 USD |
| 2/12/2026 | 18.71 USD |
| 2/11/2026 | 22.27 USD |
| 2/10/2026 | 21.94 USD |
| 2/9/2026 | 21.73 USD |
| 2/6/2026 | 21.73 USD |
| 2/5/2026 | 21.77 USD |
| 2/4/2026 | 21.03 USD |
| 2/3/2026 | 19.91 USD |
| 2/2/2026 | 19.87 USD |
| 1/30/2026 | 20.07 USD |
| 1/29/2026 | 19.73 USD |
| 1/28/2026 | 19.61 USD |
| 1/27/2026 | 19.57 USD |
| 1/26/2026 | 19.65 USD |
| 1/23/2026 | 19.84 USD |
| 1/22/2026 | 20.07 USD |
| 1/21/2026 | 19.71 USD |
| 1/20/2026 | 19.38 USD |
| 1/16/2026 | 20.11 USD |
| 1/15/2026 | 20.37 USD |
| 1/14/2026 | 19.84 USD |
| 1/13/2026 | 19.65 USD |
| 1/12/2026 | 20.15 USD |
| 1/9/2026 | 21.07 USD |
| 1/8/2026 | 20.69 USD |
| 1/7/2026 | 20.40 USD |
| 1/6/2026 | 20.55 USD |
| 1/5/2026 | 19.89 USD |
| 1/2/2026 | 19.50 USD |
| 12/31/2025 | 19.11 USD |
| 12/30/2025 | 19.30 USD |
| 12/29/2025 | 19.25 USD |
| 12/26/2025 | 19.38 USD |
| 12/24/2025 | 19.11 USD |
| 12/23/2025 | 18.93 USD |
| 12/22/2025 | 18.98 USD |
| 12/19/2025 | 18.96 USD |
| 12/18/2025 | 19.07 USD |
| 12/17/2025 | 19.29 USD |
| 12/16/2025 | 19.05 USD |
| 12/15/2025 | 19.53 USD |
| 12/12/2025 | 19.15 USD |
| 12/11/2025 | 18.90 USD |
| 12/10/2025 | 18.26 USD |
| 12/9/2025 | 18.16 USD |
| 12/8/2025 | 18.16 USD |
| 12/5/2025 | 18.54 USD |
| 12/4/2025 | 18.48 USD |
| 12/3/2025 | 18.89 USD |
| 12/2/2025 | 18.84 USD |
| 12/1/2025 | 19.08 USD |
| 11/28/2025 | 18.74 USD |
| 11/26/2025 | 18.91 USD |
| 11/25/2025 | 18.66 USD |
| 11/24/2025 | 18.18 USD |
| 11/21/2025 | 18.31 USD |
| 11/20/2025 | 17.42 USD |
| 11/19/2025 | 17.69 USD |
| 11/18/2025 | 18.15 USD |
| 11/17/2025 | 17.77 USD |
| 11/14/2025 | 18.47 USD |
| 11/13/2025 | 18.70 USD |
| 11/12/2025 | 18.70 USD |
| 11/11/2025 | 18.25 USD |
| 11/10/2025 | 17.75 USD |
| 11/7/2025 | 18.00 USD |
| 11/6/2025 | 17.98 USD |
| 11/5/2025 | 17.95 USD |
| 11/4/2025 | 17.94 USD |
| 11/3/2025 | 18.21 USD |
| 10/31/2025 | 18.47 USD |
| 10/30/2025 | 19.16 USD |
| 10/29/2025 | 22.42 USD |
| 10/28/2025 | 22.86 USD |
| 10/27/2025 | 23.17 USD |
| 10/24/2025 | 23.02 USD |
| 10/23/2025 | 22.99 USD |
| 10/22/2025 | 22.93 USD |
| 10/21/2025 | 22.75 USD |
| 10/20/2025 | 23.13 USD |
| 10/17/2025 | 23.09 USD |
| 10/16/2025 | 22.97 USD |
| 10/15/2025 | 22.75 USD |
| 10/14/2025 | 22.82 USD |
| 10/13/2025 | 22.11 USD |
| 10/10/2025 | 21.95 USD |
| 10/9/2025 | 22.51 USD |
| 10/8/2025 | 22.75 USD |
| 10/7/2025 | 22.90 USD |
| 10/6/2025 | 23.15 USD |
| 10/3/2025 | 23.86 USD |
| 10/2/2025 | 23.23 USD |
| 10/1/2025 | 23.36 USD |
| 9/30/2025 | 22.77 USD |
| 9/29/2025 | 22.38 USD |
| 9/26/2025 | 21.98 USD |
| 9/25/2025 | 21.71 USD |
| 9/24/2025 | 22.56 USD |
| 9/23/2025 | 22.86 USD |
| 9/22/2025 | 22.81 USD |
| 9/19/2025 | 23.02 USD |
| 9/18/2025 | 23.69 USD |
| 9/17/2025 | 23.20 USD |
| 9/16/2025 | 23.87 USD |
| 9/15/2025 | 23.80 USD |
| 9/12/2025 | 23.99 USD |
| 9/11/2025 | 24.49 USD |
| 9/10/2025 | 23.98 USD |
| 9/9/2025 | 24.45 USD |
| 9/8/2025 | 24.09 USD |
| 9/5/2025 | 24.42 USD |
| 9/4/2025 | 23.58 USD |
| 9/3/2025 | 23.54 USD |
| 9/2/2025 | 24.17 USD |
| 8/29/2025 | 24.69 USD |
| 8/28/2025 | 24.40 USD |
| 8/27/2025 | 24.53 USD |
| 8/26/2025 | 24.50 USD |
| 8/25/2025 | 24.56 USD |
| 8/22/2025 | 24.54 USD |
| 8/21/2025 | 23.85 USD |
| 8/20/2025 | 24.27 USD |
| 8/19/2025 | 24.33 USD |
| 8/18/2025 | 23.61 USD |
| 8/15/2025 | 24.18 USD |
| 8/14/2025 | 24.45 USD |
| 8/13/2025 | 24.11 USD |
| 8/12/2025 | 23.98 USD |
| 8/11/2025 | 23.46 USD |
Baxter International Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Baxter International Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEB USD |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEB USD |
| EBITB USD |
| EBIT MARGIN% |
| NET INCOMEB USD |
| NET INCOME GROWTH% |
| DIVIDENDDIV.USD |
| DIVIDEND GROWTHDIV. GROWTH% |
| SHARESM |
| 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 9.41 | 10.72 | 9.97 | 10.16 | 10.58 | 11.10 | 11.36 | 11.67 | 12.15 | 10.06 | 10.36 | 10.64 | 11.24 | 11.35 | 11.58 | 11.90 |
| -32.46 | 13.87 | -7.01 | 1.96 | 4.14 | 4.87 | 2.37 | 2.74 | 4.05 | -17.20 | 3.01 | 2.66 | 5.72 | 0.95 | 2.00 | 2.82 |
| 44.22 | 42.74 | 41.59 | 40.50 | 42.27 | 42.88 | 41.90 | 39.30 | 38.86 | 35.29 | 40.06 | 37.46 | 30.05 | 30.05 | 30.05 | 30.05 |
| 4.16 | 4.58 | 4.15 | 4.12 | 4.47 | 4.76 | 4.76 | 4.59 | 4.72 | 3.55 | 4.15 | 3.98 | 3.38 | 3.41 | 3.48 | 3.58 |
| 0.50 | 0.66 | 0.45 | 0.75 | 1.29 | 1.71 | 1.08 | 1.62 | 1.35 | -2.84 | 0.71 | 0.01 | -0.27 | -0.25 | -0.25 | -0.26 |
| 5.27 | 6.12 | 4.50 | 7.33 | 12.17 | 15.41 | 9.51 | 13.84 | 11.11 | -28.19 | 6.82 | 0.13 | -2.37 | -2.17 | -2.17 | -2.17 |
| 2.01 | 2.50 | 0.97 | 4.97 | 0.60 | 1.55 | 1.00 | 1.10 | 1.28 | -2.43 | 2.66 | -0.65 | -0.96 | 0.98 | 1.01 | 1.09 |
| -13.50 | 24.11 | -61.23 | 412.91 | -87.88 | 156.81 | -35.25 | 10.09 | 16.52 | -289.49 | -209.17 | -124.44 | 47.46 | -202.40 | 2.86 | 8.33 |
| 1.92 | 2.05 | 1.27 | 0.51 | 0.61 | 0.73 | 0.85 | 0.96 | 1.09 | 1.15 | 1.16 | 1.04 | 0.52 | 0.04 | 0.04 | 0.04 |
| 22.29 | 6.77 | -38.05 | -59.84 | 19.61 | 19.67 | 16.44 | 11.76 | 13.68 | 6.48 | 0.87 | -10.34 | -50.00 | -92.31 | – | – |
| 548.00 | 547.00 | 550.00 | 551.00 | 556.00 | 538.00 | 516.00 | 516.00 | 507.00 | 507.00 | 507.00 | 510.00 | 514.00 | 514.00 | 514.00 | 514.00 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Baxter International generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Baxter International retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Baxter International's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Baxter International has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Baxter International's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Baxter International stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Baxter International Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Baxter International business model & stock analysis
Baxter International SWOT Analysis
Strengths
1. Strong Market Position: Baxter International Inc holds a significant market share in the healthcare industry, especially in the field of medical devices and pharmaceuticals.
2. Diverse Product Portfolio: The company offers a wide range of products, including renal therapies, anesthesia products, surgical equipment, and pharmaceuticals, which helps in catering to different customer needs.
3. Global Presence: Baxter has a strong global presence, with operations in multiple countries, allowing it to capitalize on emerging markets and diverse customer base.
Weaknesses
1. Product Recalls: Baxter has faced product recalls in the past, which have affected its reputation and consumer confidence. The company needs to focus on improving its quality control processes.
2. Dependence on Key Customers: Baxter has a significant reliance on a few key customers for a substantial portion of its revenue. This dependency poses a risk if those customers choose to shift to competitors or face financial difficulties.
3. High R&D Costs: The research and development expenses of Baxter are substantial, and the company needs to ensure that the investments result in successful product innovations and market differentiation.
Opportunities
1. Growing Aging Population: With the global population aging, there is a growing demand for healthcare products and services, creating an opportunity for Baxter to expand its customer base.
2. Increasing Healthcare Expenditure: Governments and individuals are allocating more funds towards healthcare expenditure, providing an opportunity for Baxter to generate higher sales and revenues.
3. Technological Advancements: Advancements in technology, such as telemedicine and digital health platforms, present opportunities for Baxter to develop innovative products and solutions to meet the changing needs of healthcare providers and patients.
Threats
1. Intense Competition: Baxter operates in a highly competitive industry, facing competition from both established players and new entrants. This competition can impact market share and pricing power.
2. Regulatory Compliance: Compliance with stringent regulations and varying healthcare policies across different countries can create challenges for Baxter in terms of product approvals, pricing, and market access.
3. Economic Factors: Global economic instability, currency fluctuations, and healthcare budget cuts in certain regions can pose threats to Baxter's financial performance and growth prospects.
Baxter International Employees
3 Years
5 Years
10 Years
25 Years
Max
Details
Baxter International Segments
Baxter International Revenue by Segment (1/6)
3 Years
Max
Details
Baxter International Revenue by Segment (2/6)
3 Years
5 Years
10 Years
Max
Details
Baxter International Revenue by Segment (3/6)
3 Years
5 Years
Max
Details
Baxter International Revenue by Segment (4/6)
3 Years
5 Years
10 Years
Max
Details
Baxter International Revenue by Segment (5/6)
3 Years
Max
Details
Baxter International Revenue by Segment (6/6)
3 Years
5 Years
Max
Details
Baxter International Revenue by Region
3 Years
5 Years
10 Years
Max
Details
Baxter International Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Baxter International historical P/E ratio, EBIT multiple, and P/S ratio
Baxter International annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Baxter International shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Baxter International stock splits
Baxter International Dividend History
38 years of dividend payments
Baxter International dividend history and estimates
3 Years
5 Years
10 Years
25 Years
Max
Details
Baxter International dividend payout ratio
3 Years
5 Years
10 Years
25 Years
Max
Details
Current Baxter International forecasts and price targets in August 2026
Analyst Price Targets 2026Baxter International Analyst Rating Actions
| Date | Firm | Action | Rating | Reliability |
|---|---|---|---|---|
| 7/31/2026 | Maintained | Equal Weight | 56 | |
| 7/31/2026 | Maintained | Hold | 60 | |
| 7/31/2026 | Maintained | Hold | – | |
| 7/31/2026 | Upgrade | SellNeutral | 48 | |
| 7/28/2026 | Maintained | Neutral | 51 | |
| 7/28/2026 | Maintained | Hold | – | |
| 7/27/2026 | Maintained | Hold | 60 | |
| 7/15/2026 | Maintained | Neutral | – | |
| 7/6/2026 | Maintained | Outperform | 62 | |
| 5/28/2026 | Downgrade | NeutralSell | 48 |
Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.
Baxter International Earnings Calls
Baxter International Earnings Estimates & Surprises
| Date | EPS estimate | EPS Actual | Revenue Estimate | Price reaction | Quarterly report |
|---|---|---|---|---|---|
| 7/30/2026 | 0.37USD | - | 2.83 BUSD | - | 2026 Q2 |
| 4/30/2026 | 0.32USD | - | 2.65 BUSD | - | 2026 Q1 |
| 2/12/2026 | 0.54USD | - | 2.85 BUSD | - | 2025 Q4 |
| 4/25/2024 | 0.66USD | - | 3.66 BUSD | - | 2024 Q1 |
| 2/7/2024 | 0.87USD | - | 3.83 BUSD | - | 2023 Q4 |
| 7/26/2023 | 0.87USD | - | 3.79 BUSD | - | 2023 Q2 |
| 4/26/2023 | 0.81USD | - | 3.67 BUSD | - | 2023 Q1 |
| 2/15/2023 | 0.96USD | - | 3.82 BUSD | - | 2022 Q4 |
| 10/27/2022 | 0.82USD | - | 3.83 BUSD | - | 2022 Q3 |
| 7/28/2022 | 0.88USD | - | 3.94 BUSD | - | 2022 Q2 |
EESG©
Eulerpool ESG Scorecard© for the Baxter International stock
EEnvironment
20
Environment
SSocial
20
Social
GGovernance (Corporate Governance)
4
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
Baxter International shareholder structure
| % | Name |
|---|---|
15.56876% | |
12.65251% | |
11.22639% | |
9.07153% | |
6.57000% | |
4.70458% |
Baxter International Beneficial Ownership Filings (SEC 13D/G)
| Stake | Holder | Filing |
|---|---|---|
27.99% | SEC ↗ | |
19.40% | SEC ↗ | |
12.70% | SEC ↗ | |
12.20% | SEC ↗ | |
12.20% | SEC ↗ | |
11.33% | SEC ↗ | |
11.20% | SEC ↗ | |
10.80% | SEC ↗ | |
10.36% | SEC ↗ | |
10.36% | SEC ↗ |
Baxter International Executives and Management Board
19 members · avg. age 61 · 37 % women
Ms. Heather Knight (53)
Chief Operating Officer, Executive Vice President, Interim Group President, Medical Products and Therapies
6.60 M USD
Management
Mr. Joel Grade (54)
Chief Financial Officer, Executive Vice President
Mr. David Rosenbloom (65)
Executive Vice President, General Counsel
Mr. Alok Sonig (52)
Executive Vice President, Group President - Pharmaceuticals
Dr. Jeanne Mason (69)
Chief Human Resources Officer, Executive Vice President
Mr. Andrew Hider (48)
President, Chief Executive Officer, Director · since 2025
Mr. James Borzi (62)
Executive Vice President and Chief Supply Chain Officer
Board of Directors
Mr. D. Brent Shafer (67)
Non-Executive Chairman of the Board · since 2022
Dr. Stephen Oesterle (74)
Independent Director
Dr. David Wilkes (68)
Independent Director
Ms. Nancy Schlichting (70)
Lead Independent Director
Ms. Catherine Smith (61)
Independent Director
Ms. Amy Mcbride-Wendell (64)
Independent Director
Baxter International Supply Chain
Baxter International Supply Chain
Correlation: how closely stock prices move together
| # | Name | Trend | |||
|---|---|---|---|---|---|
| 1 | 0.72 | 0.12 | 0.35 |
| # | Name | Trend | |||
|---|---|---|---|---|---|
| 1 | 0.85 | 0.36 | — | ||
| 2 | Miromatrix Medical | 0.27 | — | — | |
| 3 | Takeda Pharmaceutical Company Limited | -0.28 | -0.25 | — | |
| 4 | bioMérieux S.A. | 0.74 | 0.31 | — | |
| 5 | Syngene International Limited | 0.02 | -0.03 | -0.35 |
Frequently asked questions about Baxter International
The business model of Baxter International Inc. is centered around developing, manufacturing, and marketing a broad portfolio of products and therapies for patients with life-threatening medical conditions. Baxter provides essential healthcare solutions across the clinical areas of critical care, nutrition, renal, and pharmaceuticals. The company's products and services aim to support healthcare professionals in improving patient outcomes and enhancing overall medical care. Baxter International Inc. operates globally and collaborates with various stakeholders in the healthcare industry to deliver innovative solutions that address unmet medical needs.
Baxter International Inc is primarily active in the healthcare industry. As a global leader in medical technology, Baxter specializes in providing innovative solutions for hospitals, clinics, and home care settings. The company focuses on various segments within healthcare, including renal care, acute therapies, and medication delivery. With a wide range of products and services, Baxter plays a vital role in enhancing patient care and improving outcomes across the healthcare continuum.
The main competitors of Baxter International Inc in the market include Johnson & Johnson, Fresenius Medical Care AG & Co. KGaA, and Becton, Dickinson and Company.
Baxter International Inc., based in Deerfield, Illinois, is a renowned American healthcare company with a rich history and impressive background. Established in 1931, Baxter has consistently excelled in developing and manufacturing medical products and technologies, specializing in biotherapeutics, renal care, and medication delivery. With a commitment to advancing patient care, Baxter has grown to become a global leader in the healthcare industry. Over the years, the company has introduced numerous innovative and life-saving solutions, including intravenous therapies, vaccines, and devices for dialysis. With its dedication to meeting critical healthcare needs worldwide, Baxter International Inc. continues to be a prominent player in the medical field.
Over the years, Baxter International Inc has achieved numerous significant milestones, solidifying its position in the healthcare industry. One notable achievement is the development of innovative medical products and therapies that have improved patient outcomes globally. Baxter International Inc has also demonstrated its commitment to sustainability by implementing eco-friendly practices and receiving recognition for its environmental efforts. Additionally, the company has expanded its international presence through strategic acquisitions and collaborations, further strengthening its global footprint. Overall, Baxter International Inc's dedication to innovation, sustainability, and global expansion has propelled it to become a leading player in the healthcare sector.
Baxter International Inc is primarily present in numerous countries and regions globally. This healthcare company operates in North America, including the United States, Canada, and Mexico. It has a strong presence in Europe, spanning countries like Germany, France, Italy, and the United Kingdom. Baxter International Inc also has significant operations in the Asia-Pacific region, with a focus on countries such as China, Japan, India, and Australia. Additionally, the company maintains a presence in Latin America, including Brazil, Argentina, and Chile. With its extensive global reach, Baxter International Inc serves a diverse range of markets and communities worldwide.
Baxter International Inc represents values of integrity, innovation, and collaboration. With a corporate philosophy focused on improving patient outcomes, the company strives to provide high-quality healthcare products and services worldwide. Baxter International Inc is committed to advancing medicine through its diverse portfolio of medical devices, pharmaceuticals, and biotechnology solutions. As a global leader, Baxter International Inc consistently emphasizes ethical practices, regulatory compliance, and sustainability. By actively investing in research and development, Baxter International Inc aims to drive positive changes in healthcare and enhance the well-being of patients globally.
Analysts currently set an average price target of 23.61 USD for the Baxter International stock (median: 22.44 USD), implying -14.3 % versus the latest price. The consensus is based on 25 analyst ratings.
25 analysts currently rate the Baxter International stock: 2 recommend buying, 16 holding and 7 selling. For 2026, analysts expect Baxter International to generate revenue of 11.35 B USD and earnings per share of 1.91 USD.
Converted at the current exchange rate, the Baxter International share trades at 23.39 EUR (27.01 USD).
The Baxter International share (BAX) is listed on 11 stock exchanges, including: NYSE (BAX), XETRA (BTL.DE), Frankfurt (BTL.F), München (BTL.MU), Düsseldorf (BTL.DU), Hamburg (BTL.HM), London (0QK8.L), London (0QK8.L).
Baxter International Inc is a US-based company operating in the healthcare and pharmaceutical sectors. The company provides medical products and services to supply patients worldwide. It is divided into three main business segments: Hospital Products, Renal Products, and Clinical Nutrition. Hospital Products is the largest segment and offers a variety of products including infusion solutions, injectables, medical devices, and concentrated solutions. Renal Products includes products and services for dialysis treatment, home hemodialysis, and acute kidney failure. Baxter also manufactures dialysis machines and accessories, as well as dialysis containers and concentrates. Clinical Nutrition also offers specialized nutrition products and preparations for parenteral nutrition. The company is a leading provider of parenteral nutrition products, including amino acids, carbohydrates, fat emulsions, and electrolytes. Baxter International also manufactures blood products such as plasma products and clotting factors. Additionally, the company offers specially processed biological products that can be used to treat conditions such as hemophilia and immunodeficiency. The company also operates an advanced life sciences business focused on drug development and medical devices. Baxter International collaborates with numerous global partners and develops innovative technologies in oncology and other areas of medical research. Baxter International is a company focused on proactive solutions to improve patient care and provide safe, effective, and high-quality medical products. The company is also committed to sustainable development and environmental protection by optimizing its materials and energy sources and continuously improving its production technology. In summary, Baxter International is a company dedicated to the development and provision of high-quality medical products and services. Through its various business segments, the company offers a wide range of products and services for different medical conditions to improve the medical care of patients worldwide. The company has also committed to sustainable and environmentally friendly production to fulfill its responsibility to society and the environment.
The expected revenue of Baxter International is 11.35 B USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Baxter International is 980.13 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Baxter International is currently 14.16. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Baxter International stock.
The price-to-sales ratio (P/S) of Baxter International is currently 1.22. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Baxter International stock.
The Eulerpool Quality Score for Baxter International is 1/10.
The ISIN of Baxter International is US0718131099. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Baxter International is 853815. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Baxter International is BAX. The ticker symbol is used to trade Baxter International shares on the stock exchange.
Over the past 12 months, Baxter International paid a dividend of 0.52 USD . This corresponds to a dividend yield of about 1.93 %. For the coming 12 months, Baxter International is expected to pay a dividend of 0.04 USD.
The current dividend yield of Baxter International is 1.93 %.
Baxter International pays a dividend, distributed in the months of , , , .
Baxter International paid dividends every year for the past 37 years.
For the upcoming 12 months, dividends amounting to 0.04 USD are expected. This corresponds to a dividend yield of 0.15 %.
Baxter International is assigned to the 'Health' sector.
To receive the latest dividend of Baxter International from amounting to 0.01 USD, you needed to have the stock in your portfolio before the ex-date on .
The last dividend was paid out on .
In the year 2025, Baxter International distributed 1.04 USD as dividends.
The dividends of Baxter International are distributed in USD.
Baxter International stock
Baxter International Peer Group
Baxter International Ticker
Baxter International FIGI
All fundamentals and in-depth analysis of Baxter International
Our stock analysis for Baxter International stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Baxter International. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.